The financial markets may remain volatile but Keros Therapeutics (NASDAQ: KROS) managed to raise more money in its public market debut than it had initially planned.
Late Tuesday the Lexington, MA-based company offered 6 million shares for $16 apiece, the high end of its projected price range. Keros had previously planned to offer 5 million shares in the range of $14 to $16 each. Those shares are set to begin trading on the Nasdaq exchange on Wednesday under the stock symbol “KROS.”
Today it has $96 million to advance the development of its investigational drugs for patients with blood and… Read more »
UNDERWRITERS AND PARTNERS
